Physicians/Specialists
Facilities/Hospitals
Publication Date: 
2021-11-03

Please note, this communication applies to Healthy Blue + MedicareSM (HMO D-SNP) offered by Blue Cross and Blue Shield of North Carolina (Blue Cross NC).


The Medical Policies, Clinical Utilization Management (UM) Guidelines, and Third-Party Criteria below were developed and/or revised to support clinical coding edits. Note, several policies and guidelines were revised to provide clarification only and are not included. Existing precertification requirements have not changed.


Please share this notice with other members of your practice and office staff.


To view a guideline, visit https://medpol.providers.amerigroup.com/green-provider/medical-policies-and-clinical-guidelines.

Notes/Updates:
Updates marked with an asterisk (*) notate that the criteria may be perceived as more restrictive.

  • *CG-SURG-112 — Carpal Tunnel Decompression Surgery
    • Outlines the Medically Necessary and Not Medically Necessary criteria for carpal tunnel decompression surgery
  • *CG-SURG-113 — Tonsillectomy with or without Adenoidectomy for Adults
    • Outlines the Medically Necessary and Not Medically Necessary criteria
  • *DME.00043 — Neuromuscular Electrical Training for the Treatment of Obstructive Sleep Apnea or Snoring
    • The use of a neuromuscular electrical training device is considered Investigational & Not Medically Necessary for the treatment of obstructive sleep apnea or snoring
  • *GENE.00058 — TruGraf Blood Gene Expression Test for Transplant Monitoring
    • TruGraf blood gene expression test is considered Investigational & Not Medically Necessary for monitoring immunosuppression in transplant recipients and for all other indications
  • LAB.00040 — Serum Biomarker Tests for Risk of Preeclampsia
    • Serum biomarker tests to diagnosis, screen for, or assess risk of preeclampsia are considered Investigational & Not Medically Necessary
  • *LAB.00042 — Molecular Signature Test for Predicting Response to Tumor Necrosis Factor Inhibitor Therapy
    • Molecular signature testing to predict response to Tumor Necrosis Factor inhibitor (TNFi) therapy is considered Investigational & Not Medically Necessary for all uses, including but not limited to guiding treatment for rheumatoid arthritis
  • *OR-PR.00007 — Microprocessor Controlled Knee-Ankle-Foot Orthosis
    • Outlines the Medically Necessary and Not Medically Necessary criteria for the use of a microprocessor controlled knee-ankle-foot orthosis
  • *SURG.00032 — Patent Foramen Ovale and Left Atrial Appendage Closure Devices for Stroke Prevention
    • Added Medically Necessary statement for transcatheter closure of left atrial appendage (LAA) for individuals with non-valvular atrial fibrillation for the prevention of stroke when criteria are met
    • Revised Investigational & Not Medically Necessary statement for transcatheter closure of left atrial appendage when the criteria are not met
  • *SURG.00077 — Uterine Fibroid Ablation: Laparoscopic, Percutaneous, or Transcervical Image Guided Techniques
    • Added Medically Necessary statement on use of laparoscopic or transcervical radiofrequency ablation
    • Added Not Medically Necessary statement on use of laparoscopic or transcervical radiofrequency ablation when criteria in Medically Necessary statement are not met
    • Removed laparoscopic radiofrequency ablation from Investigational & Not Medically Necessary statement
    • Removed Investigational & Not Medically Necessary statement on radiofrequency ablation using a transcervical approach

Medical Policies
On August 12, 2021, the Medical Policy and Technology Assessment Committee (MPTAC) approved the following Medical Policies applicable to Blue Cross NC. These guidelines take effect January 17, 2022.

Publish date Medical Policy # Medical Policy title New or revised
10/6/2021 *DME.00043 Neuromuscular Electrical Training for the Treatment of Obstructive Sleep Apnea or Snoring New
10/6/2021 *GENE.00058 TruGraf Blood Gene Expression Test for Transplant Monitoring New
10/6/2021 *LAB.00040 Serum Biomarker Tests for Risk of Preeclampsia New
10/6/2021 *LAB.00042 Molecular Signature Test for Predicting Response to Tumor Necrosis Factor Inhibitor Therapy New
10/6/2021 *OR-PR.00007 Microprocessor Controlled Knee-Ankle-Foot Orthosis New
8/19/2021 *SURG.00032 Patent Foramen Ovale and Left Atrial Appendage Closure Devices for Stroke Prevention Revised
8/19/2021 *SURG.00077 Uterine Fibroid Ablation: Laparoscopic, Percutaneous or Transcervical Image Guided Techniques Revised
8/19/2021 SURG.00119 Endobronchial Valve Devices Revised
8/19/2021 SURG.00121 Transcatheter Heart Valve Procedures Revised

 

Clinical UM Guidelines
On August 12, 2021, the MPTAC approved the following Clinical UM Guidelines applicable to Blue Cross NC. These guidelines adopted by the medical operations committee for our members on September 23, 2021. These guidelines take effect January 17, 2022.

Publish date Clinical UM Guideline # Clinical UM Guideline title New or revised
10/6/2021 *CG-SURG-112 Carpal Tunnel Decompression Surgery New
10/6/2021 *CG-SURG-113 Tonsillectomy with or without Adenoidectomy for Adults New
10/6/2021 CG-DME-44 Electric Tumor Treatment Field (TTF) Revised
8/19/2021 CG-GENE-22 Gene Expression Profiling for Managing Breast Cancer Treatment Revised
8/19/2021 CG-MED-55 Site of Care: Advanced Radiologic Imaging Revised
8/19/2021 CG-SURG-82 Bone-Anchored and Bone Conduction Hearing Aids Revised

 

https://www.bluecrossnc.com/providers/blue-medicare-providers/healthy-blue-medicare

BLUE CROSS®, BLUE SHIELD® and the Cross and Shield Symbols are registered marks of the Blue Cross and Blue Shield Association, an association of independent Blue Cross and Blue Shield Plans. Blue Cross and Blue Shield of North Carolina (Blue Cross NC) is an independent licensee of the Blue Cross and Blue Shield Association. 

BNCCARE-220-21 October 2021